|Title:||Immunohistochemisrty Screening to Increase the Efficiency of Next Generation Sequencing for Detection of Rare NTRK, ROS1, and ALK Gene Fusions in Sarcoma Patients|
|Date/Time:||Friday, November 11, 2016, 6:15 PM - 7:00 PM, Lisbon time|
The Loxo phase II 'basket' study of larotrectinib is expected to complete patient enrollment in early 2017 and report results in the second half of the year.
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Six patients, all with TRK fusion cancers unresponsive to current therapies, reported tumor shrinkage following treatment with Loxo's drug LOXO-101.